Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum KaloBios Pharmaceuticals, Inc. KBIO

"KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company focuses on developing medicines for patients with neglected and rare diseases through innovative and responsible business models."

OTCPK:KBIO - Post Discussion

KaloBios Pharmaceuticals, Inc. > reopens down 80-90%
View:
Post by thedave2006 on Jan 13, 2016 10:45am

reopens down 80-90%

bye bye.....yet another scam goes bye bye.....some lotto ticket with gains while others lost big including fellow that shorted and learnt valuable lesson.
Comment by RadioDude on Jan 13, 2016 11:03pm
He shorted at 2 bucks. Could of closed today in the morning with a gain....poor guy. On a side note. I missed another trade here. 1000 bucks would of been 4 grand eod. I saw a qoute for this right near the lows this morning too...Oh well. Not my kinda stock by any means. One to watch and learn from :) Cheers.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities